KUALA LUMPUR, The Universiti Malaya Medical Centre (PPUM) has enhanced its cancer treatment capabilities with the establishment of a laboratory dedicated to cell and gene therapy (CGT) as well as Chimeric Antigen Receptor-T Cell (CAR-T) therapy. In a statement today, PPUM said that the construction of the RM6 million laboratory, equipped with advanced facilities for cancer treatment, was the result of its collaboration with Auxi Therapeutics Sdn Bhd, a company specialising in providing T-cell-based immunotherapies for cancer treatment. It said that the therapy for treating cancer and other severe diseases has demonstrated promising results by effectively targeting and eliminating cancer cells with high precision. According to PPUM director Prof Dr Nazirah Hasnan, the establishment of treatment facilities for this disease marks another significant milestone in healthcare development and the introduction of innovative treatments. 'Through this Auxi Therapeutics GMP CAR-T and CGT Laboratory, we continue to t ake steps forward with hope and new discoveries, including innovative therapies and the formulation of more effective treatment methods for patients. 'The seriousness demonstrated by Auxi Therapeutics in pursuing research and development in cell and genetic therapy is in line with PPUM's mission to provide world-class healthcare services to patients,' according to the statement. In addition, the laboratory has the capability to provide patients with Dendritic Cell-Cytokine-Induced Killer Cell (DC-CIK) therapy. Meanwhile, Auxi Therapeutics group managing director Choo Yan Ho said CAR-T and CGT therapy are medical treatment methods designed to accommodate patients' genetic profiles and disease traits. He said that the laboratory holds the potential to generate a notable positive impact within the region and globally. 'This laboratory contributes significantly to strengthening the healthcare sector and alleviating the burden of cancer on individuals, families, and society by offering accessible and effectiv e CAR-T and CGT therapy,' he said. The facility will also house a specialised section for the production of viral vectors essential for genetic modification in CAR-T therapy treatment, ensuring compliance with rigorous standards both locally and globally, encompassing Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), and Good Tissue Practice (GTP). Source: BERNAMA News Agency